Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
7
×
Tags
biotech
boston blog main
7
×
life sciences
national blog main
boston top stories
clinical trials
fda
national top stories
eli lilly
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
amgen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
allergan
migraine research foundation
national
teva pharmaceutical
abbvie
calcitonin gene-related peptide
chronic migraine
eptinezumab
erenumab
europe blog main
What
fda
won
7
×
approval
drug
migraine
new
class
decades
developed
drugs
friday
medicine
oral
second
therapeutics
therapy
acute
addresses
agency
aimmune
alkermes
allergy
amgen
antipsychotic
approved
arguments
august
awarded
benefits
betting
big
billion
bio
biopharma
biotech
busy
candidates
causes
caveats
commercialized
Language
unset
Current search:
won
×
photo
×
" boston blog main "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines